Huntington's Disease Clinical Trial Landscape
Data updated: May 20, 2026
104 clinical trials tracked since 2008
Huntington's Disease is being studied across 104 clinical trials registered since 2008, with 21 programs currently active. The competitive pipeline includes 5 active Phase 3 trials, 16 active Phase 2 trials, and 11 active Phase 1 trials. Top industry sponsors include Roche, Skyhawk Therapeutics, Inc., Novartis.
21 active
/
104 total (since 2008)
11
Phase 1 Active
46 total
16
Phase 2 Active
58 total
5
Phase 3 Active
17 total
0
Phase 4 Active
1 total
Top Industry Sponsors
Sorted by active Active Done Failed
Roche 3 3 0
Skyhawk Therapeutics, Inc. 3 0 0
Novartis 2 0 2
UniQure Biopharma B.V. 2 0 0
Luye Pharma Group Ltd. 1 3 0
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT07326709 RECRUITING
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
Novartis Pharmaceuticals n=770
NCT06873334 ACTIVE NOT RECRUITING
Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease
Skyhawk Therapeutics, Inc. n=120
NCT07378644 RECRUITING
Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease
Skyhawk Therapeutics, Inc. n=400
NCT04713982 ACTIVE NOT RECRUITING
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
Vanderbilt University Medical Center n=30
NCT04826692 COMPLETED
TEsting METformin Against Cognitive Decline in HD
Instituto de Investigacion Sanitaria La Fe n=60
+ 12 more Phase 3 trials — see full database below
Huntington's Disease — Trials Started by Year (last 10 years)
2016 2
2017 5
2018 3
2019 6
2020 4
2021 5
2022 8
2023 5
2024 4
2025 5
2026 6
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Roche 6
Skyhawk Therapeutics, Inc. 3
Novartis 4
UniQure Biopharma B.V. 2
Luye Pharma Group Ltd. 4
Alnylam Pharmaceuticals 1
Sarepta Therapeutics, Inc. 1
ExoRNA Bioscience 1
AskBio France, SAS, a subsidiary of AskBio Inc. 1
Vico Therapeutics B. V. 1
Active Trials by Phase
Phase 1 11
Phase 2 16
Phase 3 5
Enrollment Size Distribution
1-50 58
51-200 28
201-500 14
501-1k 3
1k+ 0
All Industry Sponsors
Sorted by active Active Done Failed
Roche 3 3 0
Skyhawk Therapeutics, Inc. 3 0 0
Novartis 2 0 2
UniQure Biopharma B.V. 2 0 0
Luye Pharma Group Ltd. 1 3 0
Alnylam Pharmaceuticals 1 0 0
Sarepta Therapeutics, Inc. 1 0 0
ExoRNA Bioscience 1 0 0
AskBio France, SAS, a subsidiary of AskBio Inc. 1 0 0
Vico Therapeutics B. V. 1 0 0
Pfizer 0 11 1
Wave Life Sciences Ltd. 0 1 4
Prilenia 0 4 1
Supernus Pharmaceuticals, Inc. 0 3 1
Siena Biotech S.p.A. 0 4 0
NCT07326709 RECRUITING
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
Novartis Pharmaceuticals n=770
NCT06873334 ACTIVE NOT RECRUITING
Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease
Skyhawk Therapeutics, Inc. n=120
NCT07537075 ENROLLING BY INVITATION
An Extension of SKY-0515 in Participants With Huntington's Disease
Skyhawk Therapeutics, Inc. n=500
NCT07378644 RECRUITING
Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease
Skyhawk Therapeutics, Inc. n=400
NCT04713982 ACTIVE NOT RECRUITING
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
Vanderbilt University Medical Center n=30
NCT05655520 TERMINATED
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease
Supernus Pharmaceuticals, Inc. n=153
NCT04826692 COMPLETED
TEsting METformin Against Cognitive Decline in HD
Instituto de Investigacion Sanitaria La Fe n=60
NCT04556656 COMPLETED
PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD
Prilenia n=499
NCT03854019 COMPLETED
Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease
The University of Texas Health Science Center, Houston n=20
NCT03842969 COMPLETED
An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies
Hoffmann-La Roche n=236
NCT00665223 COMPLETED
A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease
Teva Branded Pharmaceutical Products R&D, Inc. n=437
NCT01897896 COMPLETED
Alternatives for Reducing Chorea in Huntington Disease
Auspex Pharmaceuticals, Inc. n=119
NCT00632645 COMPLETED
Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride
Assistance Publique - Hôpitaux de Paris n=180
NCT01085266 TERMINATED
An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease
Medivation, Inc. n=362
NCT00920946 COMPLETED
A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease
Medivation, Inc. n=403
NCT00608881 TERMINATED
Coenzyme Q10 in Huntington's Disease (HD)
Massachusetts General Hospital n=609
NCT00712426 TERMINATED
Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)
Massachusetts General Hospital n=553
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only